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Abstract 
Background: Malaria cases persist in some remote areas in Sabah and Sarawak despite the ongoing and largely suc-
cessful malaria control programme conducted by the Vector Borne Disease Control Programme, Ministry Of Health, 
Malaysia. Point mutations in the genes that encode the two enzymes involved in the folate biosynthesis pathway, 
dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) enzymes confer resistance to pyrimethamine 
and sulfadoxine respectively, in both Plasmodium falciparum and P. vivax. The aim of the current study was to deter-
mine the mutation on both pvdhfr at codon 13, 33, 57, 58, 61, 117, and 173 and pvdhps genes at codon 383 and 553, 
which are potentially associated with resistance to pyrimethamine and sulfadoxine in P. vivax samples in Sabah.
Methods: Every individual was screened for presence of malaria infection using a commercial rapid dipstick assay, 
ParaMax-3™ (Zephyr Biomedical, India). Individuals tested positive for P. vivax had blood collected and parasite DNA 
extracted. The pvdhfr and pvdhps genes were amplified by nested-PCR. Restriction fragment length polymorphism 
(RFLP) was carried out for detection of specific mutations in pvdhfr at codons 13Leu, 33Leu, 57Ile/Leu, 58Arg, 61Met, 
117Asn/Thr, and 173Leu and pvdhps at codons 383Gly and 553Gly. The PCR–RFLP products were analysed using the 
Agilent 2100 Bioanalyzer (Agilent Technology, AS).
Results: A total of 619 and 2119 individuals from Kalabakan and Kota Marudu, respectively participated in the study. 
In Kalabakan and Kota Marudu, 9.37 and 2.45 % were tested positive for malaria and the positivity for P. vivax infection 
was 4.2 and 0.52 %, respectively. No mutation was observed at codon 13, 33 and 173 on pvdhfr and at codon 553 on 
pvdhps gene on samples from Kalabakan and Kota Marudu. One-hundred per cent mutations on pvdhfr were at 57Leu 
and 117Thr. Mutation at 58Arg and 61Met was observed to be higher in Kota Marudu 72.73 %. Mutation at 383Gly on 
pvdhps was highest in Kalabakan with 80.77 %. There are four distinct haplotypes of pvdhfr/pvdhps combination.
Conclusions: The presence of triple and quintuple mutation combination suggest that the P. vivax isolates exhibit a 
high degree of resistant to sulfadoxine, pyrimethamine and sulfadoxine-pyrimethamine combination therapy.
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Background
Malaysia is pursuing malaria elimination and has 
a national goal to eliminate malaria by 2020, and 
categorizes as in pre-elimination phase by the World 
Health Organization [1]. In Malaysia, malaria cases 
showed a decreased in 2010, 2011, 2012, and 2013, but 
slightly increased in 2014; incidents of malaria were 6650, 
5306, 4725, 3850, and 3923, respectively [2]. Malaria is 
endemic in Sabah and most of the malaria cases occurs in 
remote areas of the interior region of Sabah or those areas 
along the borders of Malaysia-Indonesia, where mosquito 
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vectors and infected individuals are present. Inadequate 
transport and communication facilities to these areas are 
a problem for access to diagnosis and treatment and pose 
challenges for control programmes. Sabah shares borders 
with North Kalimantan of Indonesia in the south, facing 
Sebatik Island, partly within Malaysia and partly within 
Indonesia. This geographic location, together with popu-
lation movement, could facilitate malaria transmission in 
the country.
Since 2006, malaria cases in Malaysia were mostly 
attributed to Plasmodium vivax, which contributed to 
more than 50 % of malaria infection, followed by P. fal-
ciparum. However in 2014, the trend changed, when P. 
knowlesi infection was recorded in the highest number 
of cases, 65.9 % of all malaria cases in Malaysia, followed 
by P. vivax and P. falciparum, 18.6 and 9.2  %, respec-
tively. Most human malaria and zoonotic malaria cases in 
Malaysia come from Sabah, followed by Sarawak [2].
Plasmodium vivax was considered to cause benign and 
uncomplicated cause of illness, but with new molecular 
tools, it is evident that P. vivax parasite infection could 
also be involved in multiple organ dysfunction and cause 
of severe malaria similar to P. falciparum in adults and 
children, including infants [3, 4].
According to the Malaysia National Antibiotic Guide-
line 2008, the treatment for vivax malaria is chloroquine 
and primaquine. However, for mixed infection cases 
(co-infection of P. falciparum and P. vivax), the treat-
ment is similar to P. falciparum [5]. In the past, chloro-
quine (CQ) was the first-line anti-malarial drug used for 
the treatment of malaria. Sulfadoxine-pyrimethamine 
(SP), also known as Fansidar®, was used in areas with 
suspected CQ-resistance and for the treatment of mixed 
infection cases. Mixed infection of P. falciparum and P. 
vivax is frequent and thus the use of SP is likely to have 
exposed P. vivax to this drug. The use of SP in the treat-
ment of uncomplicated falciparum malaria started in 
1976. By 1996 resistance to SP was observed to be widely 
distributed in Peninsular Malaysia [6]. Additionally, SP 
combination is still occasionally used as presumptive 
treatment for individuals suspected of malaria in remote 
areas where diagnosis and treatment is not accessible. 
Therefore, P. vivax populations are often exposed to SP 
pressure and this might have caused the selection of the 
SP-resistant allele in P. vivax isolates [7].
Molecular epidemiology studies have shown that 
the point mutations in the genes that encode the two 
enzymes involved in the folate biosynthesis pathway, 
dihydrofolate reductase (DHFR) and dihydropteroate 
synthase (DHPS) enzymes confer resistance to pyrimeth-
amine and sulfadoxine, respectively, in both laboratory 
[8] and in natural parasite populations, in both P. falcipa-
rum and P. vivax parasites [9, 10]. Molecular studies have 
identified more than 20 different alleles for pvdhfr, of 
which mutations at codon 57Leu, 58Arg, 61Met, 117Thr/
Asn, and 173Ile have been reported to be involved in 
clinical antifolate resistance. The presence of double 
mutation at codon 58Arg and 117Thr and triple muta-
tion at codon 57Leu, 58Arg and 117Thr at pvdhfr gene 
are associated with delayed parasite clearance following 
SP treatment [11]. Quadruple mutations at 57Leu, 58Arg, 
61Met, and 117Thr in this gene corresponded to thera-
peutic failure of SP treatment among P. vivax-infected 
patients [12, 13]. Five mutations have been identified on 
the pvdhps gene at codons 382, 383, 442, 512, 553, and 
585. Mutation at codon 382Ala/Cys, 383Gly, 512Met/
Thr/Glu, and 553Gly of pvdhps is associated with sulf-
adoxine resistance [13, 14].
Pvdhfr mutant alleles of 58Arg and 117Thr/Asn were 
found in the southeast Asian countries of East Timor 
[15], Thailand [11, 16], Myanmar [16], Vietnam and Phil-
ippines [17], and India [18]. Mutation in pvdhps at amino 
acids 383Gly and 553Gly were highly prevalent in Thai-
land [19, 20]. In Malaysia, P. falciparum dhfr and dhps 
genes have been studied extensively in endemic areas of 
Sabah, the villages in the districts of Kalabakan, Tawau 
bordering to North Kalimantan [21], the interior part of 
Sabah, Keningau, and Nabawan [22]. Both studies have 
indicated the high prevalence of mutation in pfdhfr and 
pfdhps conferring resistance to SP, which could predict 
treatment failure.
The aim of the current study was to investigate the fre-
quency of mutation on both pvdhfr and pvdhps genes 
potentially associated with resistance to pyrimethamine 
and sulfadoxine in P. vivax field isolates in malaria-
endemic areas of Sabah. This study will establish an epi-
demiological map of the distribution of SP-resistant vivax 
malaria in Sabah. The information obtained could con-




Plasmodium vivax samples were collected from 23 vil-
lages in Kota Marudu, and 26 villages, road construction 
and loggers’ camps in Kalabakan, Sabah. Kalabakan is 
located 100 km from Tawau, towards the south of Sabah 
bordering Kalimantan, Indonesia while Kota Marudu is 
located in Kudat Division in the northern region of Sabah 
with 1083 km from Philippine (Fig. 1). The samples from 
Kalabakan were collected in 2008 and 2009 by active case 
detection. During those years, Kalabakan contributed to 
most of the malaria cases with 21.54 and 22.79 %, respec-
tively, of the total cases in Sabah (Vector Borne Disease 
Control, 2008, 2009 unpublished data). Sample collec-
tions in Kota Marudu in 2011 and 2012 were by both 
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active case detection and passive case detection. At the 
time the study was conducted, the number of malaria 
cases in Kota Marudu contributed 10  % of total cases 
in Sabah in 2011 (Vector Borne Disease Control, 2011 
unpublished data).
Sample collection
The study protocol was reviewed and approved by the 
Research Review Committee of the Institute for Medical 
Research (IMR) and Medical Research Ethics Commit-
tee (MREC), Ministry of Health Malaysia. For active case 
detection, the team visited the villages and the study was 
announced and briefed to all the population. Study infor-
mation sheets were given to all who came to the briefing. 
All the population received the study information sheet, 
informed consent form and they were assisted whenever 
required in understanding the study. Individuals who 
consented to participate in the study were screened for 
malaria infection by finger-prick blood diagnosis in the 
field using rapid diagnosis test (RDT) kit (Paramax-3™, 
Zephyr Biomedicals, India). Some finger-prick blood 
was also used to prepare blood film for malaria parasite 
(BFMP) for determination of parasite density.
Individuals diagnosed positive for malaria infection 
by RDT had approximately 500 µl of blood collected by 
venipuncture and transferred to EDTA tubes. BFMP and 
blood in anticoagulant EDTA tubes were brought to the 
field station to be processed. The EDTA blood was spot-
ted onto filter paper 3MM® Whatman (Brentford, UK). 
The filter paper was allowed to dry completely by hanging 
on a wire line in the field station. After drying, they were 
packed into a small plastic zipper bags containing silica 
gels, labelled appropriately and transported to Institute 
for Medical Research for further molecular study. The 
BFMP were stained with Giemsa and examined for pres-
ence of malaria parasites by microscopy to determine the 
Fig. 1 Map of Sabah showing the geographical sites where the 37 P. vivax isolates were collected: Kota Marudu (n = 11), Kalabakan (n = 26). In this 
study, samples were collected from two of Sabah divisions (illustrated in the square in top left corner), from Kota Marudu district in the Kudat Divi-
sion and Kalabakan district in the Tawau Division. This map were generated by OpenStreetMap: http://www.openstreetmap.org/ and USGS National 
Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/
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density of the infection. Individuals diagnosed positive 
with malaria were treated with a standard anti-malaria 
treatment by health clinic staff. The study managed to 
collect 58 samples from Kalabakan and 52 samples from 
Kota Marudu.
DNA extraction and molecular diagnosis for confirmation 
of malaria species
Parasite DNA was extracted from blood spot filter paper 
by using QIAamp® DNA Mini Kit (QIAmp; QIAGEN, 
Hilden, Germany) following the manufacturer’s instruc-
tion (Dried Blood Spot Protocol). The DNA was eluted 
with 150  µl AE Buffer (10  mM Tris–HCl pH 9.0 and 
0.5 mM EDTA). The parasite DNA was used for molec-
ular diagnosis of the malaria species and for genotyping 
studies. All samples underwent molecular speciation 
using Fuehrer et  al. [23] for P. falciparum, P. vivax and 
Plasmodium malariae. All samples also underwent spe-
ciation for P. knowlesi using protocol from Imwong et al. 
[24]. Samples confirmed positive for P. vivax infection by 
the molecular diagnosis were included in the study.
Amplification of pvdhfr and pvdhps gene
The pvdhfr and pvdhps genes were amplified from 
genomic DNA by nested-PCR. The amplifications of the 
pvdhfr was carried out as described previously [11, 25] 
with some modification on the final volume of the PCR 
reaction mix. In the amplification of P. vivax dhfr-ts gene, 
size of 1876 bp, excluding the stop codon, the PCR reac-
tion was amplified by using the oligonucleotide pair VDT 
OF and VDT OR. The final volume of the reaction mix 
was 50 µl, consisted of 50 ng of template DNA, 1X Buffer 
I-Taq (BioRad Laboratories Inc), 125 µM dNTPs (BioRad 
Laboratories Inc), 2.0  mM of Magnesium (Mg) (BioRad 
Laboratories Inc), 200 nM of each primer, and 2.5 U i-Taq 
DNA polymerase (BioRad Laboratories Inc). The cycling 
parameters for the amplification reactions were as fol-
low: an initial denaturation step at 95  °C for 5  min was 
followed by 25 cycles of denaturation steps at 94  °C for 
1 min, annealing steps at 68 °C for 2 min and extension at 
72 °C for 2 min. PCR product were hold at 16 °C after a 
final extension at 72 °C for 5 min.
Two microlitre of the PCR reaction was then used to 
amplify the P. vivax dhfr (pvdhfr) domain of size 711 bp 
by using oligonucleotide pair VDT OF and VDF OR (first 
PCR). The PCR reaction mixtures were the same as used 
in the first PCR reaction except for the Mg concentration 
and the primer concentration. The cycling temperature 
was also similar to the first PCR amplification except for 
the annealing temperature and the number of cycles (see 
Table 1).
Nested PCR were carried out separately to amplify 
three regions on the pvdhfr genes. The PCR reaction 
used primer pairs VDF13NF and VDFNR58 amplify-
ing 232 base pair (bp) fragment containing Ile13Leu, 
Pro33Leu, Ser58Arg, and Thr61Met, primer pair using 
VDNF58and VDF NR amplifying 472  bp fragment con-
taining Phe58Ile/Leu and Ser117Thr/Asn, and primer 
pair VDTOF and VDFNR amplifying 608  bp fragment 
containing Phe58Ile/Leu and Ile173Leu. The PCR reac-
tion were similar to the PCR reaction of the first PCR, 
except for the concentration of Mg and primer concen-
tration. The cycling temperature was also similar to that 
of the first PCR except for the annealing temperature and 
the cycles (see Table 1).
Amplification of the P. vivax dhps (pvdhps) gene 
was carried out as described previously [19]. The first 
round PCR was performed by using the primer sets 
VDHPS OF and VDHPS OR, followed by two sets 
of second round PCR using primer sets VDHPS NF 
and VDHPS NR amplifying 703  bp fragment contain-
ing codon Ala383Gly, and primer sets VDHPS-553OF 
and VDHPS NR amplifying 170  bp fragment contain-
ing codon 553. The first and second rounds PCR were 
carried out in a final volume of 50 µl with similar reac-
tion as carried out for pvdhfr, except for the primers 
and Mg concentration and the cycling temperature (see 
Table 2).
The PCR products were electrophoresed on 2  % aga-
rose gel (Biorad Laboratories Inc) with GelTed™ Nucleic 
Acid Gel Stain and visualized on an ultraviolet transillu-
minator. The lack of cross-contamination was monitored 
by the inclusion of negative control samples (water was 
used to replace the DNA template) in each of amplifica-
tions carried out.
RFLP (Restriction fragment length polymorphism) 
for detection of specific mutations in pvdhfr and pvdhps
The presence of mutations on pvdhfr at codons 13Leu, 
33Leu, 57Ile/Leu, 58Arg, 61Met, 117Asn/Thr, and 
173Leu and mutation on pvdhps at codons 383Gly and 
553Gly were analysed by RFLP following protocol as 
described previously [7]. The enzyme digestions were 
conducted according to manufacturer’s instruction 
(New England Biolabs, Beverly, MA, USA). Details of 
the restriction enzymes used and the digestion prod-
uct sizes indicating wild type and mutant are described 
in Table 3. The detection of mutation at 13Leu, 33Leu, 
58Arg, 61Met, and 173Leu was determined by HaeII, 
SacII, AluI, Tsp451, and StyI, respectively. The detec-
tion of mutation at 57Ile/Leu was determined by reac-
tion of PCR (VDT-OF/VDFNR) with Xmn1, which did 
not cleave the 608  bp product. To confirm the muta-
tion, either 57Ile or 57Leu, the PCR (VDNF57/VDF 
NR) was digested with BsrGI to digest the 472 bp prod-
ucts to 444 and 28 bp (mutation 57Ile) and no digestion 
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(mutation 57Leu). The detection of mutation 117Thr/
Asn was determined by reaction of PCR (VDNF57/
VDF NR) with PvuII, which did not digest the 472  bp 
product. The codon Ser117Thr was determined by 
reaction with BsrI, which did not digest the 472  bp. 
The mutation at 117Thr was determined by reaction 
with BstNI, which cleaved the 472  bp product to 258 
and 215  bp. The mutation at 117Asn was determined 
by reaction with BsrI which cleaved the 472 bp to 253 
and 219 bp. The mutation at 117Asn was confirmed by 
reaction with BstNI, which did not cleave the 472  bp 
product. Amplification of pvdhps gene, region VDHPS 
NF/VDHPS NR, detected mutation at 383Gly. The 
mutation was detected by reaction of the PCR prod-
uct with MspI, which cleaved the 703  bp product to 
655 and 48 bp. The mutation at 553Gly was detected by 
reaction of PCR VDHPS553OF/VDHPSNR with MscI, 
which did not digest the 170 bp.
Analysis of PCR–RFLP products using the Agilent 2100 
Bioanalyzer
The PCR–RFLP products were analysed using the Agi-
lent 2100 Bioanalyzer and the Agilent DNA 1000 Kit 
(Agilent Technologies, Molecular Probes Inc, USA). The 
procedures were conducted according to manufacturer’s 
instruction. The result was then viewed and analysed 
using Agilent 2100 software.
Results
Sample collection
A total of 619 and 2119 individuals from 23 and 26 sites 
(villagers, logger camps, road construction workers) in 
Kalabakan and Kota Marudu, respectively, participated 
in the study. In Kalabakan, 58 individuals (9.37 %) (95 % 
[CI] 7.07–11.67) tested positive for malaria of which 26 
(4.2 %) (95 % [CI] 2.6–5.8 %) were positive for P. vivax. 
While in Kota Marudu, 52 individuals (2.45  %) (95  % 
[CI]1.8–3.1  %) tested positive for malaria of which 11 
(0.52 %) (95 % [CI] 0.2–0.8 %) were positive for P. vivax. 
Total number of P. vivax samples used in the study was 
37. The pvdhfr and pvdhps genes were successfully ampli-
fied and RFLP analysis for detection of mutation on the 
genes was conducted.
Analysis of mutation on the pvdhfr and pvdhps genes
Findings of the pvdhfr gene showed presence of mutations 
at 58Arg and 61Met (Fig. 2), at 57Leu and 117Thr (Fig. 3) 
and 57Leu (Fig.  4). Findings of pvdhps gene showed 
mutation at 383Gly (Fig.  5). Wild type was observed at 
Ile13, Pro33, Ile173 on pvdhfr gene and Ala553 on pvdhps 
gene.The prevalent of wild type and mutant on pvdhfr 
and pvdhps genes is summarized in Table 4. No mutation 
was observed at codon 13, 33 and 173 on pvdhfr and at 
codon 553 on pvdhps gene on samples from Kalabakan 
and Kota Marudu. Common mutations (100 %) on pvdhfr 
Table 1 Primers and profiles used for amplification of pvdhfr gene










2.0 200 68/2 25 1876
VDT OF: ATGGAGGACCTTTCAGATGTATTTGACATT
VDF OR: CTTGCTGTAAACCAAAAAGTCCA
2.0 400 66/2 30 711
VDF 13NF: GACCTTTCAGATGTATTTGACATTTACGGC
VDF NR58: GGTACCTCTCCCTCTTCCACTTTAGCTTCT
1.5 300 62/2 30 232
VDNF57: CATGGAAATGCAACTCCGTCGATATGATGT
VDF NR: TCACACGGGTAGGCGCCGTTGATCCTCGTG
1.5 400 50/2 30 472
VDT OF: ATGGAGGACCTTTCAGATGTATTTGACATT
VDF NR: TCACACGGGTAGGCGCCGTTGATCCTCGTG
1.0 300 60/2 30 608
Table 2 Primers and profiles used for amplification of pvdhps gene










2.0 250 69/2 21 1354
VDHPS NF: AATGGCAAGTGATGGGGCGAGCGTGATTGA
VDHPS NR: CAGTCTGCACTCCCCGATGGCCGCGCCACC
2.0 250 70.5/2 25 703
VDHPS 553OF: TTCTCTTTGATGTCGGCCTGGGGTTGGCCA
VDHPS NR: CAGTCTGCACTCCCCGATGGCCGCGCCACC
2.0 250 69.5/1 30 170
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were at 57Leu and 117Thr (Table 4). Mutations at 58Arg 
and 61Met were observed to be higher in Kota Marudu, 
72.73 % (95 % [CI] 43.44–90.26). Mutation at 383Gly on 
pvdhps was highest in Kalabakan with 80.77 % (95 % [CI] 
62.12–91.49) (Table 4).    
Distribution of pvdhfr and pvdhps combination alleles
The findings showed that there are four distinct haplo-
types of pvdhfr/pvdhps combination among the 37 sam-
ples (Table 5). The four haplotypes are:
13Ile, 33Pro, 57Leu, 58Arg, 61Met, 117Thr, 173Ile, 
383Gly, 553Ala,
13Ile, 33Pro, 57Leu, 58Ser, 61Thr, 117Thr, 173Ile, 
383Gly, 553Ala,
13Ile, 33Pro, 57Leu, 58Arg, 61Met, 117Thr, 173Ile, 
383Ala, 553Ala and
13Ile, 33Pro, 57Leu, 58Ser, 61Thr, 117Thr, 173Ile, 
383Ala, 553Ala
Discussion
From 2006 to 2012, more than 50  % of malaria cases in 
Malaysia were attributed by P. vivax species, although 
recently P. knowlesi cases has been reported to be prev-
alent at Lipis Pahang in the Peninsular Malaysia and 
Sarawak, in Malaysia Borneo [26]. The malaria cases are 
decreasing; however, cases still occur in confined, remote, 
interior, hilly or forested areas of endemic regions. Malaria 
control and elimination strategy plays an important role 
in decreasing the disease burden in the country [27]. The 
present study is undertaken to investigate the prevalence 
of mutation associated with the pvdhfr and pvdhps in P. 
vivax isolates in the endemic areas of Kalabakan and Kota 
Marudu in Sabah. In Kalabakan, of the 619 individuals 
screened for malaria, 9.37 % were positive, of which 4.2 % 
were P. vivax infection, while in Kota Marudu, of the 2119 
population screened, 2.45 % positive for malaria, of which 
0.52 % were positive for P. vivax.
Genotype analysis of the P. vivax samples identified 
that the most prevalent mutations of pvdhfr gene from 
both Kalabakan and Kota Marudu are single mutations at 
codon 57Leu (100 %) and 117Thr (100 %). Findings from 
Kuesap et al. [28] in Mae Sot area in Thailand showed a 
similar observation, where mutation at codon 117Thr was 
prevalent. Unlike this study, where mutation at 57Leu 
(100  %) was observed, the finding in Mae Sot, Thailand 
was found to be the less [28]. Recent studies from Phil-
ippine, showed that there are no mutation at acid amino 
57 meanwhile all their samples were mutant 117Asn [29].
Meanwhile, study from Indonesia showed the allele with 
the highest prevalence was 117Asn (27  %), followed by 
117Thr (18 %) [30]. However,all samples from Kalabakan 
and Kota Marudu did not contain any 117Asn mutation. 
Mutation at 57Leu and 117Thr, on its own, confers resist-
ance to pyrimethamine [11, 31] and likely to be precur-
sory to further dhfr mutations.
The present study also showed mutation at codon 
58Arg (Kalabakan 30.77  % and Kota Marudu 72.73  %) 
Table 3 The primer pairs, PCR product sizes, restriction enzymes used and  the digestion product size in  detection 
of gene polymorphism on pvdhfr and pvdhps gene




















Pro: 138 and 94
Ser: 167, 40 and 25
Thr: 200 and 32
Leu: 200 and 32
Leu: 232










Ser: 258 and 214
Ser: 472
Ser: 472
Ile: 444 and 28
Leu: 472
Asn/Thr: 472
Thr: 257 and 215
Asn: 472









Phe: 442 and 166
Ile: 472 and 136
Ile/Leu: 608








170 Ala553Gly MscI Ala: 143 and 27 Gly: 170
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and at codon 61Met (Kalabakan 30.77  % and Kota 
Marudu 72.73  %). Mutations at 57Leu, 58Arg, 61Met, 
and 117Thr have been reported to be involved in clinical 
antifolate resistance [11, 32]. In Kota Marudu, mutation 
at 58Arg and 61Met was found to be high compared to 
Kalabakan. However in Kalabakan, a higher proportion 
of the P. vivax populations are still wild type at codon 
58Arg and 61Met. Kota Marudu region is nearly with 
Philippines meanwhile Kalabakan is more nearly to Indo-
nesia. Recent study by from Philippine showed that all 
their sample represent the mutation at 58 Arg [29] com-
pare with study from Indonesia showed that their sample 
still have wild type at codon 58 (58Ser) [30]. Studies con-
ducted in the region indicated that mutation at 58Arg is 
common, similar to other regions, such as East Timor 
[15], Thailand [25], Philippines [17], and India [31].
Study of the pvdhps gene on samples collected from 
Kalabakan and Kota Marudu showed that mutation at 
codon 383Gly (80.77 and 72.73  %, respectively) is com-
mon. Mutation at codon 383Gly indicated a reduced 
sensitivity to sulfa drugs and sulfones [14, 19]. Unlike 
this study, the prevalence of 383Gly mutation is low in 
other parts of the region, East Timor [33], Iran [34], Paki-
stan [7], and Korea [16]. Similar with recent study from 
Fig. 2 PCR–RFLP of the pvdhfr gene. PCR–RFLP products of VDF13NF/VDFNR58 with HaeIII showed no cleavage of the 232 bp fragment indicating 
of wild type Ile13 (a). Reaction with SacII cleaved the PCR products to 138 and 94 bp indicating wild type Pro33 (b). Reaction with AluI cleaved the 
PCR products to 208 and 25 bp fragments, indicating a mutation 58Arg, while cleavage to 167, 40 and 25 bp indicated a wild type Ser58 (c). Reac-
tion with Tsp451 showed no cleavage (232 bp) indicating a mutation 61Met, while wild type Thr61 showed a cleavage to 200 and 32 bp fragment 
(d). a, b and d: Lane L DNA ladder of Agilent DNA 1000 Kit (Agilent Technologies, Molecular Probes Inc, USA), Lanes 1–12 PCR–RFLP products of 
samples. c: Lanes L DNA ladder of Agilent DNA 1000 Kit (Agilent Technologies, Molecular Probes Inc, USA), Lane 1–11 PCR–RFLP products of samples
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neighbouring region, Indonesia showed 50  % sample 
carried mutant allele, 383Gly meanwhile mutant allele 
553Gly was not observed in any of the isolates examined 
[30].
No mutations were detected at codon 13Leu, 33Leu 
and 173Leu of pvdhfr gene and codon 553Gly on the 
pvdhps. Mutation at codon 173Leu was found to be 
involved in clinical anti-folate resistance [25]. With the 
presence of 383Gly mutation along with double mutant 
of pvdhfr, which observed in the present study, impli-
cated the use of either pyrimethamine or sulfadoxine 
(with other anti-malarial drugs) or a combination (SP), in 
post treatment failure.
In the present findings, there are four distinct haplo-
types of pvdhfr/pvdhps. The most common combina-
tion is Ile13, Pro33, 57Leu, Ser58, Thr61, 117Thr, Ile173, 
383Gly, Ala553, (two dhfr, one dhps) (53.85 %), and was 
found to be prevalent in Kalabakan. Haplotype Ile13, 
Fig. 3 PCR–RFLP of the pvdhfr gene. PCR–RFLP product of VDNF 57/VDF NR with BsrGI showed no cleavage of the 472 bp indicating wild type 
Phe58 and mutation 57Leu (a). Reaction with PvuII showed no cleavage (472 bp) indicating mutation 117Thr/Asn (b). Reaction with BstN1 cleaved 
the 472 bp to 258 and 215 bp indicating mutation 117Thr (c). Reaction with Bsr1 showed no cleavage indicating wild type Ser118 and mutation 
117Thr (d). a, b, c and d: Lane L DNA ladder of Agilent DNA 1000 Kit (Agilent Technologies, Molecular Probes Inc, USA), Lanes 1–12 PCR–RFLP prod-
ucts of samples
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Pro33, 57Leu, 58Arg, 61Met, 117Thr, Ile173, 383Gly, 
Ala553, (four dhfr, one dhps) was observed in both Kala-
bakan and Kota Marudu. Clinical studies have showed 
that quadruple pvdhfr mutant parasite (57Leu, 58Arg, 
61Met, 117Thr), had been associated with SP treatment 
failure [9, 11, 32]. The mutant parasite in this study, 
strongly suggested that P. vivax isolates from Kalabakan 
and Kota Marudu carry the resistant allele to antifolate 
drugs, SP. This observation is also seen in neighbouring 
countries, Indonesia, Papua New Guinea and India [9, 
35].
Mutation combinations at 57Leu, 58Arg with 383Gly 
and 58Arg, 117Thr with 383Gly, have been implicated 
in reducing sensitivity to SP drugs in P. vivax population 
Fig. 4 PCR–RFLP of the pvdhfr gene. PCR–RFLP of VDTOF/VDFNR with StyI cleaved the 608 bp fragment into 472 and 136 bp indicating of wild type 
Ile173 (a). Reaction with XmnI showed no cleavage (608 bp) indicating mutation 57Ile/Leu (b). a and b: Lane L DNA ladder of Agilent DNA 1000 Kit 
(Agilent Technologies, Molecular Probes Inc, USA). Lanes 1–12 PCR-RFLP products of samples
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[36], and mutation at 58Arg and 117Thr has been impli-
cated in in  vivo pyrimethamine resistance as it could 
cause structural changes in pvdhfr and lead to decrease 
binding to the drug [37], and appeared first under drug 
pressure [34]. One in  vitro study at Indonesia, showed 
that most of samples that carried the quadruple mutant 
allele (57Arg/58Leu/61Met/117Thr) were 23 times more 
likely to experience therapeutic failure, compare with 
Fig. 5 PCR-RFLP of the pvdhps gene. PCR-RFLP of VDHPSNF/VDHPSNR with MspI cleaved the 703 bp fragment into 655 and 48 bp indicating muta-
tion 383Gly (a). PCR–RFLP of VDHPS553OF/VDHPSNR with MscI digest the 170 bp to 143 and 28 bp indicating wild type Ala553 (b). a and b: Lane L 
DNA ladder of Agilent DNA 1000 Kit (Agilent Technologies, Molecular Probes Inc, USA). a: Lanes 1, 3, 5, 7, 9, and 11 PCR products of VDHPSNF/VDHP-
SNR, Lanes 2, 4, 6, 8, 10, and 12 digestion reaction with MspI. b: Lanes 1, 3, 5, 7, 9, and 11 PCR products of VDHPS553OF/VDHPSNR, Lanes 2, 4, 6, 8, 10, and 
12 digestion reaction with MscI
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subjects infected by parasites that carried only wild type, 
single, double or triple mutant allele of dhfr [13].
Conclusion
The study suggests the presence of sulfadoxine, pyrimeth-
amine and SP pressure on P. vivax isolates in Kalabakan and 
Kota Marudu, Sabah. The presence of triple and quintuple 
mutation combination suggests that P. vivax isolates exhibit 
a high degree of resistance to sulfadoxine and pyrimeth-
amine and SP. The use of parasite molecular markers as 
tools for surveillance for drug resistance provides support 
to malaria control programmes and malaria elimination 
strategies, so that resistance status can be assessed and the 
most effective treatment can be selected and deployed.
This study served as scientific evidence that there 
is resistance to sulfadoxine, pyrimethamine and SP in 
the study area. Any malaria drug combination, such as 
artesunate plus SP and chloroquine plus SP needs to 
be reconsidered for the treatment of P. vivax infection, 
especially in the area of chloroquine and sulfadoxine-
pyrimethamine-resistant P. vivax.
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Table 4 Frequency of wild type and mutation on the dhfr and dhps gene from 37 P. vivax samples collected in Kalabakan 
and Kota Marudu, Sabah
Genes Codon Kalabakan (n = 26) Kota Marudu (n = 11)
Wild type (%) Mutant (%) Wild type (%) Mutant (%)
Pvdhfr 13 100 0 100 0
33 100 0 100 0
57 0 100 0 100
58 69.23 30.77 27.27 72.73
61 69.23 30.77 27.27 72.73
117 0 100 0 100
173 100 0 100 0
pvdhps 383 19.23 80.77 27.27 72.73
553 100 0 100 0
Table 5 Frequency distribution of the combination pvdhfr and  pvdhps from 37 P. vivax samples collected in Kalabakan 
and Kota Marudu, Sabah demonstrated four distinct haplotypes
Ile isoleucine, Leu leucine, Ser serine, Thr threonine, Pro proline, Arg arginine, Met methionine, Ala alanine, Gly glycine
Pvdhfr alleles Pvdhps alleles No of isolates (%) No of dhfr/dhps 
combination mutant 
genotypeKalabakan (n = 26) Kota Marudu (n = 11)
13Ile/33Pro/57Leu/58Arg/61Met/117Thr/173Ile 383Gly553Ala 7 (26.92) 6 (54.55) 4 dhfr, 1 dhps
13Ile/33Pro/57Leu/58Ser/61Thr/117Thr/173Ile 383Gly/553Ala 14 (53.85) 2 (18.18) 2 dhfr, 1 dhps
13Ile/33Pro/57Leu/58Arg/61Met/117Thr/173Ile 383Ala/553Ala 1 (3.85) 2 (18.18) 4 dhfr
13Ile/33Pro/57Leu/58Ser/61Thr/117Thr/173Ile 383Ala/553Ala 4 (15.38) 1 (9.09) 2 dhfr
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